Filing Details
- Accession Number:
- 0001562180-25-002291
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-03-11 16:30:23
- Reporting Period:
- 2025-03-10
- Filing Date:
- 2025-03-11
- Accepted Time:
- 2025-03-11 16:30:23
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1082554 | United Therapeutics Corp | UTHR | Pharmaceutical Preparations (2834) | 521984749 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1673232 | Michael Benkowitz | C/O United Therapeutics Corporation 1000 Spring Street Silver Spring MD 20910 | President And Coo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-03-10 | 2,000 | $111.00 | 2,000 | No | 4 | M | Indirect | by Trust |
| Common Stock | Disposition | 2025-03-10 | 193 | $313.93 | 1,807 | No | 4 | S | Indirect | by Trust |
| Common Stock | Disposition | 2025-03-10 | 200 | $317.11 | 1,607 | No | 4 | S | Indirect | by Trust |
| Common Stock | Disposition | 2025-03-10 | 316 | $319.35 | 1,291 | No | 4 | S | Indirect | by Trust |
| Common Stock | Disposition | 2025-03-10 | 533 | $320.57 | 758 | No | 4 | S | Indirect | by Trust |
| Common Stock | Disposition | 2025-03-10 | 358 | $321.62 | 400 | No | 4 | S | Indirect | by Trust |
| Common Stock | Disposition | 2025-03-10 | 300 | $322.86 | 100 | No | 4 | S | Indirect | by Trust |
| Common Stock | Disposition | 2025-03-10 | 100 | $323.99 | 0 | No | 4 | S | Indirect | by Trust |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Indirect | by Trust |
| No | 4 | S | Indirect | by Trust |
| No | 4 | S | Indirect | by Trust |
| No | 4 | S | Indirect | by Trust |
| No | 4 | S | Indirect | by Trust |
| No | 4 | S | Indirect | by Trust |
| No | 4 | S | Indirect | by Trust |
| No | 4 | S | Indirect | by Trust |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options | Disposition | 2025-03-10 | 2,000 | $0.00 | 2,000 | $111.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2021-03-15 | 2028-03-15 | No | 4 | M | Indirect |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 2,648 | Direct |
Footnotes
- This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024.
- Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power.
- This transaction was executed in multiple trades at prices ranging from $316.76 to $317.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder ofthe issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $319.09 to $320.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder ofthe issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $320.09 to $320.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder ofthe issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $321.10 to $321.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder ofthe issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $322.285 to $323.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder ofthe issuer full information regarding the number of shares and prices at which the transaction was effected.
- Includes 71 shares of common stock acquired on March 4, 2025 under the United Therapeutics Employee Stock Purchase Plan.
Billionaire Hedge Funds
